Literature DB >> 18760436

The vaccinia virus fusion inhibitor proteins SPI-3 (K2) and HA (A56) expressed by infected cells reduce the entry of superinfecting virus.

Peter C Turner1, Richard W Moyer.   

Abstract

The orthopoxvirus SPI-3 (K2) and A56 (hemagglutinin, HA) proteins interact and together prevent cell-cell fusion. SPI-3/A56 has been proposed to prevent the superinfection of previously infected cells by reducing virus-cell fusion. Binding of mature virions of vaccinia virus (VV) to VV-infected cells was unaffected by SPI-3 or A56 on the surface of infected cells. Entry of VV into infected cells was assessed using VV-P(T7)-luc carrying the luciferase reporter under T7 control. Cells infected with VV or cowpox virus (CPV) expressing T7 RNA polymerase and lacking SPI-3 and/or A56 were superinfected with VV-P(T7)-luc, and luciferase activity was measured. Inactivation of SPI-3 or A56 from the pre-infecting virus resulted in greater luciferase expression from the superinfecting VV-P(T7)-luc. Antibody against SPI-3 present during infection with wild-type CPV-T7 increased luciferase expression from superinfecting VV-P(T7)-luc. The SPI-3/A56 complex on the infected cell surface therefore appears to reduce the entry of virions into infected cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18760436      PMCID: PMC2668523          DOI: 10.1016/j.virol.2008.07.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  35 in total

1.  An orthopoxvirus serpinlike gene controls the ability of infected cells to fuse.

Authors:  P C Turner; R W Moyer
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Product review. New mammalian expression vectors.

Authors:  B Moss; O Elroy-Stein; T Mizukami; W A Alexander; T R Fuerst
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

3.  Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex.

Authors:  Suany Ojeda; Arban Domi; Bernard Moss
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway.

Authors:  Alan C Townsley; Andrea S Weisberg; Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex.

Authors:  Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

6.  Two distinct low-pH steps promote entry of vaccinia virus.

Authors:  Alan C Townsley; Bernard Moss
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

7.  The envelope G3L protein is essential for entry of vaccinia virus into host cells.

Authors:  Ruzan A Izmailyan; Cheng-Yen Huang; Shamim Mohammad; Stuart N Isaacs; Wen Chang
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  A vaccinia serine protease inhibitor which prevents virus-induced cell fusion.

Authors:  K M Law; G L Smith
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

9.  Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions.

Authors:  George C Katsafanas; Bernard Moss
Journal:  Cell Host Microbe       Date:  2007-10-11       Impact factor: 21.023

10.  Superinfection exclusion of vaccinia virus in virus-infected cell cultures.

Authors:  L Christen; J Seto; E G Niles
Journal:  Virology       Date:  1990-01       Impact factor: 3.616

View more
  23 in total

1.  Vaccinia mature virus fusion regulator A26 protein binds to A16 and G9 proteins of the viral entry fusion complex and dissociates from mature virions at low pH.

Authors:  Shu-Jung Chang; Ao-Chun Shih; Yin-Liang Tang; Wen Chang
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells.

Authors:  Nancy Y Villa; Eric Bartee; Mohamed R Mohamed; Masmudur M Rahman; John W Barrett; Grant McFadden
Journal:  Virology       Date:  2010-03-24       Impact factor: 3.616

3.  Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion.

Authors:  Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

Review 4.  Poxvirus proteomics and virus-host protein interactions.

Authors:  Kim Van Vliet; Mohamed R Mohamed; Leiliang Zhang; Nancy Yaneth Villa; Steven J Werden; Jia Liu; Grant McFadden
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

Review 5.  The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.

Authors:  Brian C DeHaven; Kushol Gupta; Stuart N Isaacs
Journal:  J Gen Virol       Date:  2011-06-29       Impact factor: 3.891

6.  The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein.

Authors:  Kaori Shinoda; Linda S Wyatt; Bernard Moss
Journal:  Virology       Date:  2010-06-17       Impact factor: 3.616

7.  A novel mode of poxvirus superinfection exclusion that prevents fusion of the lipid bilayers of viral and cellular membranes.

Authors:  Jason P Laliberte; Bernard Moss
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

8.  The E6 protein from vaccinia virus is required for the formation of immature virions.

Authors:  Olga Boyd; Peter C Turner; Richard W Moyer; Richard C Condit; Nissin Moussatche
Journal:  Virology       Date:  2010-02-08       Impact factor: 3.616

Review 9.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

10.  Induction of cell-cell fusion by ectromelia virus is not inhibited by its fusion inhibitory complex.

Authors:  Noam Erez; Nir Paran; Galia Maik-Rachline; Boaz Politi; Tomer Israely; Paula Schnider; Pinhas Fuchs; Sharon Melamed; Shlomo Lustig
Journal:  Virol J       Date:  2009-09-29       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.